AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) has been assigned a consensus rating of “Reduce” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The […]
Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) have received an average recommendation of “Reduce” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the […]
Shares of AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) have earned a consensus rating of “Reduce” from the six analysts that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and one has given a buy recommendation to the […]
AlloVir, Inc. (NASDAQ:ALVR – Get Free Report) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 7,700,000 shares, a drop of 32.0% from the December 15th total of 11,320,000 shares. Based on an average daily volume of 1,790,000 shares, the short-interest ratio is […]
AlloVir Inc. a developer of cell therapies intended to treat viral diseases, said Thursday that its board had approved a roughly 95% reduction to its staff,.